Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06345898

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

Clinical Study on the Safety and Efficacy of JWK002 Injection Administered as a Single Subretinal Injection in Subjects With X-linked Retinoschisis

Status
Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
West China Hospital · Academic / Other
Sex
Male
Age
5 Years – 18 Years
Healthy volunteers
Not accepted

Summary

This trial is to evaluate the safety and efficacy of JWK002 treatment of X-linked retinoschisis(XLRS). This study will enroll subjects aged 5-18 years old to receive a sub-retinal injection of JWK002.

Conditions

Interventions

TypeNameDescription
DRUGJWK002Subretinal administration of gene therapy vector JWK002 to one eye.

Timeline

Start date
2023-11-17
Primary completion
2033-11-30
Completion
2033-11-30
First posted
2024-04-03
Last updated
2025-02-07

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06345898. Inclusion in this directory is not an endorsement.

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS (NCT06345898) · Clinical Trials Directory